Although thyroid eye disease is a common complication of Graves’ disease, the pathogenesis of the orbital disease is poorly understood. Most authorities implicate the immune response as an important causal factor. We sought to clarify pathogenesis by using gene expression microarray.
An international consortium of ocular pathologists and orbital surgeons contributed formalin fixed orbital biopsies. RNA was extracted from orbital tissue from 20 healthy controls, 25 patients with thyroid eye disease (TED), 25 patients with nonspecific orbital inflammation (NSOI), 7 patients with sarcoidosis and 6 patients with granulomatosis with polyangiitis (GPA). Tissue was divided into a discovery set and a validation set. Gene expression was quantified using Affymetrix U133 Plus 2.0 microarrays which include 54,000 probe sets.
Principal component analysis showed that gene expression from tissue from patients with TED more closely resembled gene expression from healthy control tissue in comparison to gene expression characteristic of sarcoidosis, NSOI, or granulomatosis with polyangiitis. Unsupervised cluster dendrograms further indicated the similarity between TED and healthy controls. Heat maps based on gene expression for cytokines, chemokines, or their receptors showed that these inflammatory markers were associated with NSOI, sarcoidosis, or GPA much more frequently than with TED.
Citation: Rosenbaum JT, Choi D, Wong A, Wilson DJ, Grossniklaus HE, Harrington CA, et al. (2015) The Role of the Immune Response in the Pathogenesis of Thyroid Eye Disease: A Reassessment. PLoS ONE10(9): e0137654. https://doi.org/10.1371/journal.pone.0137654
Editor: Massimo Pietropaolo, Baylor College of Medicine, UNITED STATES
Received: May 27, 2015; Accepted: August 20, 2015; Published: September 15, 2015
Copyright: © 2015 Rosenbaum et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited
Data Availability: The authors confirm that all data underlying the findings are fully available without restriction. All relevant clinical data are within the paper. The raw and normalized gene expression microarray data are available from the GEO database (accession numbers GSE58331 and GSM1407182 through GSM1407356).
Funding: This research was supported by funding from National Institutes of Health USA Grants (www.nih.gov), EY020249 (JTR), EY010572 (JTR) and RR024140 (E.S.Orwoll); and Research to Prevent Blindness (www.rpbusa.org) (Casey Eye Institute, OHSU), the Stan and Madelle Rosenfeld Family Trust (JTR), the William and Mary Bauman Foundation (JTR), the MAS Family Foundation (JTR). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: The authors have read the journal's policy and the authors of this manuscript have the following competing interests: JTR has in the past consulted for Genentech and was a co-investigator on a studied funded by Genentech to evaluate the use of rituximab for orbital inflammatory diseases. JTR is a PLOS ONE Editorial Board member. This does not alter the authors’ adherence to PLOS ONE Editorial policies and criteria. The other authors have declared that no competing interests exist.
The rationale to classify Graves’ disease as an autoimmune disease is irrefutable. Graves’ disease is characterized by an autoantibody to the thyroid stimulating hormone receptor. The biological activity of this autoantibody results in hyperthyroidism.
It is also widely believed that thyroid eye disease (TED) is autoimmune. First, it frequently coexists with Graves’ disease, so there is “guilt by association”. Many patients with Graves’, however, do not develop TED, nor is it clear that the autoantibody responsible for hyperthyroidism plays a pathogenic role in orbital disease. Thyroid eye disease is associated with polymorphisms in HLA molecules  and polymorphisms in receptors that modulate the immune response . An increase in cytokine mRNA expression has been noted in orbital tissue from patients with TED . Cells like fibroblasts or myocytes cultured from the orbit affected by TED display an increase in cytokine synthesis [4, 5]. Elevated levels of circulating cytokines have been detected in patients with TED [6, 7]. Patients with TED have an increased risk for gastrointestinal autoimmunity . Furthermore, many of the strategies aimed at the treatment of TED are based on immunosuppression [9, 10].
In order to clarify the pathogenesis of TED, we have organized a consortium of international centers. We have employed gene expression microarray to analyze the detection of transcripts in orbital tissue from patients with thyroid eye disease. While this type of analysis has been reported previously [11–15], ours is the first report to compare gene expression among different forms of orbital inflammation. By juxtaposing gene expression in TED relative to other causes of orbital inflammation, we find a surprisingly limited immune-response signature relative to several other causes of orbital inflammation.
Materials and Methods
Centers and IRB approval
This study was approved by the Institutional Review Board (IRB) at Oregon Health & Science University and at each of the other contributing centers: Columbia University IRB, University of California San Diego IRB, Wake Forest University IRB, Medical College of Wisconsin IRB, Mount Carmel (Ohio) IRB, University of Miami IRB, University of British Columbia Clinical Research Ethics Board, Royal Adelaide Hospital Research Ethics Committee, King Khaled Eye Specialist Hospital Human Ethics Committee/Institutional Review Board. Tissue acquisition was in compliance with the requirements of the local review board including acquisition of written informed consent from the donor where required. All data were anonymized and de-identified prior to analysis. The research adhered to the tenets of the Declaration of Helsinki.
Formalin-fixed, paraffin-embedded (FFPE) samples and relevant demographic and clinical data were obtained. The diagnoses of sarcoidosis, granulomatosis with polyangiitis (GPA) (previously known as Wegener’s granulomatosis), TED, nonspecific orbital inflammation (NSOI) (previously also known as orbital pseudotumor or idiopathic orbital inflammation), and normal were based on the clinical and histopathological information obtained and submitted by orbital disease specialists and ocular pathologists from their respective institutions. All biopsies were further reviewed by two of the authors (DJW and HEG) as noted below.
This is a multicenter, international study on previously biopsied orbital tissue. Biopsies of orbital adipose tissue from a total of 83 subjects were studied (20 controls with no known orbital disease, 6 with GPA, 7 with sarcoidosis, 25 with TED, and 25 with NSOI). The ages are summarized in Table 1. The gender distribution was roughly comparable among the 5 groups. Seventy-six per cent of the TED patients were female, compared to 64% of those with NSOI, 83% of those with sarcoidosis, 67% of those with GPA, and 70% of the healthy controls. Of the 25 patients with TED, 15 were biopsied prior to starting therapy, four had received prior corticosteroid therapy, and one had received local radiation. Prior therapy information was not provided on 5 patients. Nineteen of the 25 patients were known to be hyperthyroid, one was hypothyroid, and 3 were euthyroid. Thyroid status was not provided on two subjects. Twenty of the patients had orbital surgery for symptomatic relief. The reason for surgery was not stated in 5 subjects. Thyroid antibody status was reported in 5 patients and was positive in 3 of these. The control tissue was obtained during surgery such as blepharoplasty and enucleation on eyes with non-inflamed orbits.
Hematoxylin and eosin stained slides of all samples were evaluated in a masked fashion by two ocular pathologists (D.J.W. and H.E.G.) for histopathological characteristics. The diagnosis from the pathologists was compared to the diagnosis from the institution where tissue had been obtained. In some cases, additional stains were requested or additional clinical information was reviewed. A few cases with an ambiguous diagnosis were excluded. In all cases included in this study, a consensus diagnosis was obtained by Drs. Wilson and Rosenbaum, and the contributing center’s diagnosis was accepted.
Tissue Preparation and Gene Expression Profiling
RNA extraction and microarray assays were performed in the OHSU Gene Profiling Shared Resource as previously reported . We used Human U133 Plus 2.0 arrays that contain over 54,000 probe sets for 47,000 human transcripts and variants.
Affymetrix CEL files were normalized by the Robust Multiarray Analysis . Testing for potential differences in gene expression across disease groups was done by fitting linear models after controlling for sex and age at biopsy. Mean differences were considered statistically significant when there was at least 1.5-fold change with a false discovery rate adjusted p-value less than 0.05. The ‘affy’, ‘caret’ ‘MASS’, ‘limma’ and ‘randomForest’ packages in the R project (http://www.r-project.org) were used for statistical computations.
Principal component analysis (PCA) was used for two dimensional or three-dimensional visualization of the dissimilarity in gene expression profiles across the disease groups . A dendrogram that could be aligned with heat maps was created by unsupervised, hierarchical cluster analysis. The data used for the PCA plots and dendrogram were restricted to those probe sets that had significantly different signals for TED, sarcoidosis, GPA, or NSOI groups compared to normal controls. The GSEA program [19, 20] provided a means to identify expression differences in predetermined sets of genes without reliance on the FDR p-values and fold-differences used to select the probe sets employed in the creation of the dendrograms. The data used for the generation of the heat maps were restricted to 40,450 probe sets with adequate annotation and custom gene lists for immunoglobulins, cytokines, cytokine receptors, chemokines, and chemokine receptors.
Table 1 shows the mean ages for control groups and for subjects with TED in this study. Because studies based on multiple statistical comparisons are fraught with “significant” findings that merely represent chance occurrences from multiple statistical tests, we divided our subjects into a discovery and a validation set. The validation set determines if the differences found in the discovery set are reproducible.
Fig 1 shows principal component analysis (PCA) plots that compare the difference in gene expression from TED patients and from healthy controls. In a PCA, the distance between two points reflects their relative similarity or dissimilarity. For the discovery set (set 1), the separation between the two groups indicates that there are clear differences between TED and controls. For the validation set (set 2), there is again a grouping of TED distinct from the controls. However, only a minority of the probe sets that distinguished TED from controls in the discovery set were reproduced in the validation set. In fact, no probe sets indicated transcripts with a significantly higher signal (>1.5-fold increase with a false discovery rate adjusted p value of <0.05) in both the discovery set and the validation set in a comparison between TED and the healthy controls. Table 2 lists the 29 probe sets (~23 genes) that had significantly lower signals in tissue from patients with thyroid eye disease compared to tissue from non-diseased controls. Thus, TED is distinct from controls, but the distinction is not strong.
The discovery set (Set 1) had 36 significantly up-regulated and 254 significantly down-regulated probe sets. The validation set (Set 2) had 66 significantly up-regulated and 604 significantly down-regulated probe sets. At least 1.5-fold change with FDR adjusted p-value < 0.05 is considered statistically significant.
The PCA plots in Fig 2 compare gene expression in orbital tissue from patients with TED to orbital tissue from patients with sarcoidosis, NSOI, or GPA. Also included are subjects with no known history of orbital disease. The grouping clearly shows that TED is much more similar to control tissue compared to subjects with sarcoidosis, most subjects with NSOI, or patients with GPA.
C = control. T = TED. N = NSOI. S = Sarcoidosis. G = GPA. Set 1 is based on the discovery set and Set2 is based on the validation set.
Another way to represent the correspondence of complex data sets is to display the results as an unsupervised cluster dendrogram in which the height of the branches reflects the relative difference between the branches. The dendrograms at the top of Figs 3 and 4 are based on the validation set and indicate that subjects with TED display gene expression patterns that cluster with patterns for uninflamed controls in the branches labeled C and D. In contrast, the patterns for subjects with sarcoidosis or GPA are found in the A and B branches. The NSOI subject patterns are distributed more widely, but only a minority is in the C and D branches. Dendrograms for a similar analysis of the discovery set data are shown in S1 and S2 Figs. The dendrograms indicate that the TED expression pattern is more closely aligned to healthy tissue than to diseased tissue from patients with sarcoidosis, GPA, or NSOI.
The heat maps were created with the GSEA program comparing probe set signal levels for subjects in branches A and B versus branches C and D. Genes with the highest signals in branches A and B are at the top of each section. The end branch labels are N—NSOI, S—sarcoidosis, G—GPA, T—TED, C—control.
The heat maps below the dendrograms indicate the relative expression of some immunologically important transcripts: immunoglobulins, cytokines, and cytokine receptors in Fig 3 and chemokine and chemokine receptors in Fig 4. The heat map columns are aligned with the corresponding samples in the dendrogram. Heat maps for a similar analysis of the discovery set data are shown in S1 and S2 Figs. These figures indicate clearly that diseases such as GPA, sarcoidosis, and NSOI are much more associated with increased expression of these transcripts in comparison to TED.
We considered a variety of potential confounders for this study including whether the biopsy was obtained prior to therapy or subsequent to therapy and whether the patient was on corticosteroids at the time of biopsy. Surprisingly neither of these variables appears to be contributing to the results.
A recent review from respected authorities on TED concluded: “lymphocytes and cytokines are intimately involved in the initiation, amplification, and maintenance of the autoimmune process in TED.”  TED is widely considered to be an immune-mediated disease. Observations that support this include its improvement with prednisone or B cell depleting therapy , its co-existence with Graves’ disease which is driven by autoantibodies, and increased expression of cytokines in the affected orbital tissue [14, 23, 24]. However, a randomized controlled trial using B cell depletion failed to demonstrate benefit for TED . The therapeutic effect of prednisone is nonspecific since corticosteroids regulate many genes in addition to those involved in immune responses . In parallel with our investigation of TED, we have collected tissue from patients with additional forms of orbital inflammation including sarcoidosis, GPA, and NSOI. Juxtaposing gene expression from TED with gene expression from 3 other causes of exophthalmos shows that inflammatory markers are much less commonly associated with TED relative to the other two diagnoses.
We recently reported on the immunohistochemical detection of IgG4 in biopsies from patients with either orbital or lacrimal disease . IgG4 is widely accepted as a marker of immune activation . We detected IgG4 in 30% or more of subjects with GPA, sarcoidosis, or NSOI. However, substantial IgG4 staining was consistently absent in tissue from subjects with TED or healthy controls. These observations further support the contention that only a low level of inflammation generally accompanies thyroid eye disease. Our studies do not mean that the immune response has no role in the pathogenesis of TED. However, its role is relatively slight, suggesting that metabolic or other pathways might be better therapeutic targets to treat TED.
Several previous groups have attempted to clarify the pathogenesis of TED using broad amplification techniques similar to what we describe [11–15]. Our approach has advantages over prior studies. It is the first to be able to make comparisons to tissue representing other forms of orbital inflammation. It is the first to include both a discovery and a validation set. We have previously validated our microarray data using quantitative PCR and have shown a correlation of greater than 0.7 between the PCR and microarray values.
We also acknowledge limitations. While the diagnosis of TED is rarely controversial, we have relied on the clinical expertise from multiple centers such that we cannot exclude some diagnostic heterogeneity. Our gene expression data, however, support that we have studied a fairly uniform disease entity. As stated in the methods, about 60% of the patients with TED in this study were biopsied prior to starting therapy. Most of the biopsies were performed one or more years after disease onset. It is possible, therefore, that many of the biopsies were obtained after an early phase of TED that may have a more active, immune-mediated component. It is also possible that biopsy of extra-ocular muscle would have revealed an inflammatory signature that we could not detect in adipose tissue. Relief of symptoms was the motivation for most of the TED biopsies, whereas biopsies of the other diseases were primarily for diagnostic purposes. This difference might lead to the other diseases being sampled during an earlier, stage of disease, although in prior published analysis of gene expression in orbital inflammatory disease we could not demonstrate that disease duration affected levels of transcripts . Our sample numbers were too small to test for differences due to demographic variables, such as age and gender, so to compare the disease groups we used linear models after controlling for these variables. We are in the process of collecting additional biopsies to assess the role of disease duration, therapy, and site of biopsy more thoroughly. We also acknowledge that artifacts can result from multiple statistical comparisons.
Some patients with thyroid eye disease are euthyroid. Others develop orbital disease well in advance of clinical thyroid disease. We believe that this approach to gene expression profiling will complement any information that can be gleaned by light microscopy such that ultimately orbital disease will be diagnosed in part by gene expression profiling.
An analysis of the molecular pattern of gene expression in TED also has the potential to clarify pathogenesis and thus to suggest new forms of therapy. Furthermore, some patients with TED have disease which is especially protracted. We predict that gene expression will help to identify subsets of patients such as those whose disease is especially aggressive or persistent or those who are especially likely to benefit from specific forms of therapy. Our observations support an approach to therapy that is not based solely on immunosuppression.
S1 Fig. A dendrogram produced by hierarchical cluster analysis and an independently created heat map of signals for cytokine and cytokine receptor transcripts compares the expression profiles of subjects within each disease group in array dataset 1.
The end branch labels are N—NSOI, S—sarcoidosis, G—GPA, T—TED, C—control.
S2 Fig. A dendrogram produced by hierarchical cluster analysis and an independently created heat map of signals for chemokine and chemokine receptor transcripts compares the expression profiles of subjects within each disease group in array dataset 1.
The end branch labels are N—NSOI, S—sarcoidosis, G—GPA, T—TED, C—control.
RNA extraction and microarray assays were performed in the OHSU Gene Profiling Shared Resource. We are grateful to Kristina Vartanian for her excellent technical support for the microarray work.
Conceived and designed the experiments: JTR DC CAH SRP. Performed the experiments: JTR DC CAH SRP DJW HEG PS AW. Analyzed the data: JTR DC CAH SRP. Contributed reagents/materials/analysis tools: BSK CA CNC DOK DPE DS DT EAS GJH HaH HMA JAF JDN MK PJD PJP PKP RAD RPY SD VAW. Wrote the paper: JTR DC AW DJW HEG CAH RAD JDN EAS CNC JAF DT CA SD PKP GJH MK PJP VAW PJD DPE HMA HaH DS RPY BSK DOK PS SRP. Project leader: JTR. Coordinated contributing center sample and data collection: SRP.
- 1. Li R, Liu DH, Cao CN, Wang SQ, Dang RH, Lan XY, et al. Single nucleotide polymorphisms of myostatin gene in Chinese domestic horses. Gene. 2014;538(1):150–4. Epub 2013/12/26. S0378-1119(13)01688-0 [pii]. pmid:24368331.
- 2. Du P, Ma X, Wang C. Associations of CTLA4 Gene Polymorphisms with Graves' Ophthalmopathy: A Meta-Analysis. Int J Genomics. 2014;2014:537969. Epub 2014/08/15. pmid:25121088; PubMed Central PMCID: PMCPMC4121157.
- 3. Linquist RA, Symons RC, O'Bryhim B, Whittaker TJ, Sokol JA. Cytokine profiles in clinical subtypes of ophthalmic Graves' disease. Orbit. 2014;33(5):363–8. Epub 2014/07/25. pmid:25058606.
- 4. Li B, Smith TJ. PI3K/AKT pathway mediates induction of IL-1RA by TSH in fibrocytes: modulation by PTEN. J Clin Endocrinol Metab. 2014;99(9):3363–72. Epub 2014/05/21. pmid:24840811; PubMed Central PMCID: PMCPMC4154109.
- 5. Antonelli A, Ferrari SM, Corrado A, Franceschini SS, Gelmini S, Ferrannini E, et al. Extra-ocular muscle cells from patients with Graves' ophthalmopathy secrete alpha (CXCL10) and beta (CCL2) chemokines under the influence of cytokines that are modulated by PPARgamma. Autoimmun Rev. 2014;13(11):1160–6. Epub 2014/08/31. doi: S1568-9972(14)00169-4 [pii] pmid:25172242.
- 6. Wei H, Guan M, Qin Y, Xie C, Fu X, Gao F, et al. Circulating levels of miR-146a and IL-17 are significantly correlated with the clinical activity of Graves' ophthalmopathy. Endocr J. 2014;61(11):1087–92. Epub 2014/08/08. doi: DN/JST.JSTAGE/endocrj/EJ14-0246 [pii]. pmid:25100151.
- 7. Niyazoglu M, Baykara O, Koc A, Aydogdu P, Onaran I, Dellal FD, et al. Association of PARP-1, NF-kappaB, NF-kappaBIA and IL-6, IL-1beta and TNF-alpha with Graves Disease and Graves Ophthalmopathy. Gene. 2014;547(2):226–32. Epub 2014/06/24. S0378-1119(14)00702-1 [pii]. pmid:24956560.
- 8. Ponto KA, Schuppan D, Zwiener I, Binder H, Mirshahi A, Diana T, et al. Thyroid-associated orbitopathy is linked to gastrointestinal autoimmunity. Clin Exp Immunol. 2014;178(1):57–64. Epub 2014/06/07. pmid:24903731.
- 9. Zhang L, Grennan-Jones F, Draman MS, Lane C, Morris D, Dayan CM, et al. Possible targets for nonimmunosuppressive therapy of Graves' orbitopathy. J Clin Endocrinol Metab. 2014;99(7):E1183–90. Epub 2014/04/25. pmid:24758182.
- 10. Salvi M. Immunotherapy for Graves' ophthalmopathy. Curr Opin Endocrinol Diabetes Obes. 2014;21(5):409–14. Epub 2014/08/12. pmid:25105999.
- 11. Ezra DG, Krell J, Rose GE, Bailly M, Stebbing J, Castellano L. Transcriptome-level microarray expression profiling implicates IGF-1 and Wnt signalling dysregulation in the pathogenesis of thyroid-associated orbitopathy. J Clin Pathol. 2012;65(7):608–13. Epub 2012/05/05. jclinpath-2012-200719 [pii]. pmid:22554965.
- 12. Planck T, Parikh H, Brorson H, Martensson T, Asman P, Groop L, et al. Gene expression in Graves' ophthalmopathy and arm lymphedema: similarities and differences. Thyroid. 2011;21(6):663–74. Epub 2011/04/23. pmid:21510802.
- 13. Chen MH, Liao SL, Chen MH, Tsou PL, Shih MJ, Chang TC, et al. Lysosome-related genes are regulated in the orbital fat of patients with graves' ophthalmopathy. Invest Ophthalmol Vis Sci. 2008;49(11):4760–4. Epub 2008/06/17. iovs.08-2020 [pii]. pmid:18552385.
- 14. Lantz M, Vondrichova T, Parikh H, Frenander C, Ridderstrale M, Asman P, et al. Overexpression of immediate early genes in active Graves' ophthalmopathy. J Clin Endocrinol Metab. 2005;90(8):4784–91. Epub 2005/06/02. jc.2004-2275 [pii] pmid:15928252.
- 15. Kumar S, Leontovich A, Coenen MJ, Bahn RS. Gene expression profiling of orbital adipose tissue from patients with Graves' ophthalmopathy: a potential role for secreted frizzled-related protein-1 in orbital adipogenesis. J Clin Endocrinol Metab. 2005;90(8):4730–5. Epub 2005/05/12. doi: jc.2004-2239 [pii] pmid:15886250; PubMed Central PMCID: PMCPMC1236982.
- 16. Rosenbaum JT, Choi D, Wilson DJ, Grossniklaus HE, Sibley CH, Harrington CA, et al. Molecular diagnosis of orbital inflammatory disease. Exp Mol Pathol. 2015;98(2):225–9. Epub 2015/01/18. doi: S0014-4800(15)00011-8 [pii] pmid:25595914; PubMed Central PMCID: PMCNIHMS655610.
- 17. Irizarry RA, Bolstad BM, Collin F, Cope LM, Hobbs B, Speed TP. Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res. 2003;31(4):e15. pmid:12582260.
- 18. Mardia KV. Some properties of classical multi-dimensional scaling. Commun Stat Theory Methods. 1978;A7:1233–41.
- 19. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 2005;102(43):15545–50. Epub 2005/10/04. doi: 0506580102 [pii] pmid:16199517; PubMed Central PMCID: PMCPMC1239896.
- 20. Mootha VK, Lindgren CM, Eriksson KF, Subramanian A, Sihag S, Lehar J, et al. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet. 2003;34(3):267–73. Epub 2003/06/17. sng1180 [pii]. pmid:12808457.
- 21. Shan SJ, Douglas RS. The pathophysiology of thyroid eye disease. J Neuroophthalmol. 2014;34(2):177–85. Epub 2014/05/14. 00041327-201406000-00017 [pii]. pmid:24821101.
- 22. Minakaran N, Ezra DG. Rituximab for thyroid-associated ophthalmopathy. Cochrane Database Syst Rev. 2013;5:CD009226. Epub 2013/06/04. pmid:23728689.
- 23. Kumar S, Bahn RS. Relative overexpression of macrophage-derived cytokines in orbital adipose tissue from patients with graves' ophthalmopathy. J Clin Endocrinol Metab. 2003;88(9):4246–50. Epub 2003/09/13. pmid:12970294.
- 24. Hiromatsu Y, Yang D, Bednarczuk T, Miyake I, Nonaka K, Inoue Y. Cytokine profiles in eye muscle tissue and orbital fat tissue from patients with thyroid-associated ophthalmopathy. J Clin Endocrinol Metab. 2000;85(3):1194–9. Epub 2000/03/17. pmid:10720061.
- 25. Stan MN, Garrity JA, Carranza Leon BG, Prabin T, Bradley EA, Bahn RS. Randomized controlled trial of rituximab in patients with Graves' orbitopathy. J Clin Endocrinol Metab. 2015;100(2):432–41. Epub 2014/10/25. pmid:25343233; PubMed Central PMCID: PMCPMC4318907.
- 26. Beck IM, Clarisse D, Bougarne N, Okret S, Haegeman G, De Bosscher K. Mitogen- and stress-activated protein kinase 1 MSK1 regulates glucocorticoid response element promoter activity in a glucocorticoid concentration-dependent manner. Eur J Pharmacol. 2013;715(1–3):1–9. Epub 2013/07/09. S0014-2999(13)00501-3 [pii]. pmid:23831393.
- 27. Wong AJ, Planck SR, Choi D, Harrington CA, Troxell ML, Houghton DC, et al. IgG4 immunostaining and its implications in orbital inflammatory disease. PLoS One. 2014;9(10):e109847. Epub 2014/10/11. PONE-D-14-25948 [pii]. pmid:25303270; PubMed Central PMCID: PMCPMC4193851.
- 28. Stone JH. IgG4-related disease: nomenclature, clinical features, and treatment. Semin Diagn Pathol. 2012;29(4):177–90. Epub 2012/10/17. S0740-2570(12)00052-4 [pii]. pmid:23068296.
- 29. Rosenbaum JT, Choi D, Wilson DJ, Grossniklaus HE, Harrington CA, Sibley CH, et al. Orbital pseudotumor can be a localized form of granulomatosis with polyangiitis as revealed by gene expression profiling. Exp Mol Pathol. 2015;Epub ahead of print. pmid:26163757.